Sanofi Entered into a Research Collaboration with Scribe Therapeutics to Advance CRISPR-based Cell Therapies for Cancer

Shots:

Scribe to receive $25M up front & will be eligible to receive ~$1B in development and commercial milestones along with royalties on net future product sales that emerge from the collaboration
Sanofi gets the non-exclusive rights to use genome editing CasX-Editor (XE) technology for multiple oncology targets & selects Scribe’s CRISPR by Design platform to expand the oncology pipeline for ex vivo cell therapies
The collaboration complements Sanofi’s robust research efforts for the NK cell therapy spectrum and provides access to scientists to use engineered CRISPR-based technologies for off-the-shelf NK cell therapies and novel combination

Ref: Bussinesswire | Image: Sanofi